Genomic Medicine Revolutionizes Heart Care: A New Standard of Practice

Notice

This is an unedited manuscript accepted for publication and provided as an Article in Press for early access at the author’s request. The article will undergo copyediting, typesetting, and galley proof review before final publication. Please be aware that errors may be identified during production that could affect the content. All legal disclaimers of the journal apply.

Year : 2025 | Volume : | : | Page : –
    By

    Aastha Parekh,

  • Richa Shah,

  • Foram Shah,

  • Viddhi Bhatt,

  • Dr. Vishwa Mehta,

  1. Assistant Professor, Department of Pharmacology, L. M. College of Pharmacy, Opp. Gujarat University, Navrangpura, Ahmedabad, Gujarat, India
  2. Assistant Professor, Department of Pharmacology, L. M. College of Pharmacy, Opp. Gujarat University, Navrangpura, Ahmedabad, Gujarat, India
  3. Assistant Professor, Department of Pharmacology, L. M. College of Pharmacy, Opp. Gujarat University, Navrangpura, Ahmedabad, Gujarat, India
  4. Assistant Professor, Department of Pharmacology, L. M. College of Pharmacy, Opp. Gujarat University, Navrangpura, Ahmedabad, Gujarat, India
  5. Assistant Professor, Department of Pharmacology, L. M. College of Pharmacy, Opp. Gujarat University, Navrangpura, Ahmedabad, Gujarat, India

Abstract

document.addEventListener(‘DOMContentLoaded’,function(){frmFrontForm.scrollToID(‘frm_container_abs_159526’);});Edit Abstract & Keyword

The integration of genomic and precision medicine into cardiovascular healthcare represents a transformative advancement in addressing the global burden of cardiovascular diseases (CVDs). Precision medicine leverages genomic, proteomic, and metabolomic data to provide personalized care, optimizing treatment outcomes while minimizing adverse effects. Over the past decade, extensive research has highlighted its potential to revolutionize the management of major CVDs, including myocardial infarction, hypertension, and heart failure, which significantly contribute to global morbidity and mortality. Genomic tools, such as polygenic risk scores (PRS) and single nucleotide polymorphisms (SNPs), enhance cardiovascular risk prediction, enabling early interventions and targeted therapies. For example, PRS has demonstrated utility in stratifying individuals with a heightened genetic predisposition to coronary artery disease. Advances in the identification of monogenic variants have also enabled personalized interventions for familial hypercholesterolemia. Furthermore, biomarkers like cardiac troponins, copeptin, and genetic variants in CYP2C19 have refined diagnostic and therapeutic strategies for acute myocardial infarction. Genomic insights into hypertension have unveiled critical pathways, offering potential targets for innovative treatments. Despite the promise, challenges such as ensuring diverse study populations and addressing ethical considerations remain. This evolving paradigm underscores the transformative impact of genomic and precision medicine, heralding a new era of individualized cardiovascular care.

Keywords: Genomic Medicine, Precision Medicine, Cardiovascular Diseases (CVDs), Polygenic Risk Scores (PRS), Single Nucleotide Polymorphisms (SNPs), Coronary Artery Disease, Familial Hypercholesterolemia, Genetic Variants, Genomic Insights.

How to cite this article:
Aastha Parekh, Richa Shah, Foram Shah, Viddhi Bhatt, Dr. Vishwa Mehta. Genomic Medicine Revolutionizes Heart Care: A New Standard of Practice. International Journal of Tropical Medicines. 2025; ():-.
How to cite this URL:
Aastha Parekh, Richa Shah, Foram Shah, Viddhi Bhatt, Dr. Vishwa Mehta. Genomic Medicine Revolutionizes Heart Care: A New Standard of Practice. International Journal of Tropical Medicines. 2025; ():-. Available from: https://journals.stmjournals.com/ijtm/article=2025/view=0

document.addEventListener(‘DOMContentLoaded’,function(){frmFrontForm.scrollToID(‘frm_container_ref_159526’);});Edit

References

  1. S. National Library of Medicine. Adherence to therapy and outcomes [Internet]. Bethesda (MD): National Center for Biotechnology Information; [cited 2025 Jan 22]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK547668/
  2. Corporate Finance Institute. Morbidity rate [Internet]. [cited 2025 Jan 22]. Available from: https://corporatefinanceinstitute.com/resources/wealth-management/morbidity-rate/
  3. S. National Library of Medicine. Adherence to therapy and outcomes [Internet]. Bethesda (MD): National Center for Biotechnology Information; [cited 2025 Jan 22]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK547668/
  4. National Cancer Institute. Complication [Internet]. [cited 2025 Jan 22]. Available from: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/complication
  5. Cleveland Clinic. Cardiovascular disease [Internet]. [cited 2025 Jan 22]. Available from: https://my.clevelandclinic.org/health/diseases/21493-cardiovascular-disease
  6. Khera AV, Chaffin M, Aragam KG, Haas ME, Roselli C, Choi SH, et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat Genet. 2018;50(9):1219-24. doi:10.1038/s41588-018-0183-z.
  7. McPherson R, Pertsemlidis A, Kavaslar N, Stewart A, Roberts R, Cox DR, et al. A common allele on chromosome 9 associated with coronary heart disease. Science. 2007;316(5830):1488-91. doi:10.1126/science.1142447.
  8. Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013;34(45):3478-90. doi:10.1093/eurheartj/eht273.
  9. Abraham G, Havulinna AS, Bhalala OG, Byars SG, De Livera AM, Yetukuri L, et al. Genomic prediction of coronary heart disease. Eur Heart J. 2016;37(43):3267-78. doi:10.1093/eurheartj/ehw450.
  10. Damask A, Steg PG, Schwartz GG, Szarek M, Hagström E, Badimon L, et al. Patients with high genome-wide polygenic risk scores for coronary artery disease may receive greater clinical benefit from alirocumab treatment in the ODYSSEY OUTCOMES trial. Circulation. 2020;141(8):624-36. doi:10.1161/CIRCULATIONAHA.119.044434.
  11. Yeung C, Lau E, Leung WK, Mak KL, et al. Predictors of cardiovascular disease in clinical cohorts. J Clin Med. 2023;12(14):4668. doi:10.3390/jcm12051799.
  12. Nanomedicine Research Group. Current advances in nanomedicine [Internet]. Wiley Online Library; 2023. Available from: https://onlinelibrary.wiley.com/doi/epdf/10.1002/nano.202300127
  13. BMC Cardiovascular Disorders. Global prevalence of myocardial infarction [Internet]. [cited 2025 Jan 22]. Available from: https://bmccardiovascdisord.biomedcentral.com/articles/10.1186/s12872-023-03231w
  14. Yeung C, Lau E, Leung WK, Mak KL, et al. Predictors of cardiovascular disease in clinical cohorts. J Clin Med. 2023;12(14):4668. doi:10.3390/jcm12051799.
  15. Mauldin K, Roper LM, Chen X. Cardiovascular risk in lifestyle intervention studies. PMC. 2010;296(5371). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2965371/
  16. Roberts R, Stewart AF. Genes and coronary artery disease: where are we? J Am Coll Cardiol. 2012;60(18):1715-21.
  17. Pasterkamp G, van der Laan SW. Genomics in coronary artery disease: unveiling new molecular mechanisms for personalized medicine. Int J Mol Sci. 2022;23(23):15008.
  18. Claassens DMF, Vos GJA, Bergmeijer TO, et al. A genotype-guided strategy for oral P2Y12 inhibitors in primary PCI. N Engl J Med. 2019;381(18):1621-31.
  19. Pereira NL, Farkouh ME, So D, et al. Effect of genotype-guided oral P2Y12 inhibitor selection vs conventional clopidogrel therapy on ischemic outcomes after percutaneous coronary intervention. JAMA. 2020;324(8):761.
  20. Schwartz PJ, Crotti L, Insolia R. Long QT syndrome: from genetics to management. Circ Arrhythm Electrophysiol. 2012;5(4):868-77.
  21. Crea F, Liuzzo G. Erosion vs. rupture: the yin-yang of plaque pathology. Circulation. 2022;145(8):625-8.
  22. Libby P, Pasterkamp G. Requiem for the ‘vulnerable plaque.’ Eur Heart J. 2015;36(43):2984-7.
  23. Pasea L, Chung SC, Cardoso VR, et al. Personalising the decision for prolonged dual antiplatelet therapy: development and validation of prognostic models. Eur Heart J. 2020;41(38):3663-74.
  24. Oni-Orisan A, Edin ML, Lee JA, et al. Epoxyeicosatrienoic acids and cardioprotection: the road to translation. J Mol Cell Cardiol. 2020;144:77-86.
  25. Thygesen K, Alpert JS, White HD. Universal definition of myocardial infarction. J Am Coll Cardiol. 2007;50(22):2173-95.
  26. Glatz JF, Luiken JJ, Bonen A. Membrane fatty acid transporters as regulators of lipid metabolism: implications for metabolic disease. Physiol Rev. 2010;90(1):367-417.
  27. Cleveland Clinic. Hypertension (high blood pressure) [Internet]. [cited 2025 Jan 22]. Available from: https://my.clevelandclinic.org/health/diseases/4314-hypertension-high-blood-pr
  28. Portland Press. Clinical Science [Internet]. [cited 2025 Jan 22]. Available from: https://portlandpress.com/clinsci/article/131/22/2671/71694
  29. BMC Public Health. Hypertension and global health studies [Internet]. [cited 2025 Jan 22]. Available from: https://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-024-20097-5
  30. Biomarker insights on hypertension [Internet]. [cited 2025 Jan 22]. Available from: https://doi.org/10.1139/bcb-2019-0045
  31. Medical News Today. Risk factors for hypertension [Internet]. [cited 2025 Jan 22]. Available from: https://www.medicalnewstoday.com/articles/risk-factors-for-hypertension
  32. World Health Organization (WHO). Hypertension fact sheet [Internet]. [cited 2025 Jan 22]. Available from: https://www.who.int/news-room/fact-sheets/detail/hypertension
  33. Biomarker insights on hypertension [Internet]. [cited 2025 Jan 22]. Available from: https://doi.org/10.1139/bcb-2019-0045
  34. Portland Press. Clinical Science [Internet]. [cited 2025 Jan 22]. Available from: https://portlandpress.com/clinsci/article/131/22/2671/71694
  35. Khera AV, Chaffin M, Aragam KG, Haas ME, Roselli C, Choi SH, et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat Genet. 2018;50(9):1219-24. doi:10.1038/s41588-018-0183-z.
  36. McPherson R, Pertsemlidis A, Kavaslar N, Stewart A, Roberts R, Cox DR, et al. A common allele on chromosome 9 associated with coronary heart disease. Science. 2007;316(5830):1488-91. doi:10.1126/science.1142447.
  37. Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013;34(45):3478-90. doi:10.1093/eurheartj/eht273.
  38. Abraham G, Havulinna AS, Bhalala OG, Byars SG, De Livera AM, Yetukuri L, et al. Genomic prediction of coronary heart disease. Eur Heart J. 2016;37(43):3267-78. doi:10.1093/eurheartj/ehw450.
  39. Damask A, Steg PG, Schwartz GG, Szarek M, Hagström E, Badimon L, Chapman MJ, Boileau C, Tsimikas S, Ginsberg HN, et al. Patients with high genome-wide polygenic risk scores for coronary artery disease may receive greater clinical benefit from alirocumab treatment in the ODYSSEY OUTCOMES trial. Circulation. 2020;141(8):624-36. doi:10.1161/CIRCULATIONAHA.119.044434.
Ahead of Print Subscription Review Article
Volume
Received 22/01/2025
Accepted 01/02/2025
Published 07/02/2025
166